The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain
Open accessAbstract
Direct-acting cannabinoid receptor agonists are well known to reduce hyperalgesic responses and allodynia after nerve injury, although their psychoactive side effects have damped enthusiasm for their therapeutic development. Alternatively, inhibiting fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the principal enzymes responsible for the degradation of the respective endogenous cannabinoids, anandamide (AEA) and 2-arachydonylglycerol (2-AG), reduce nociception in a variety of nociceptive assays, with no or minimal behavioral effects. In the present study we tested whether inhibition of these enzymes attenuates mechanical allodynia, and acetone-induced cold allodynia in mice subjected to chronic constriction injury of the sciatic nerve. Acute administration of the irreversible FAAH inhibitor, cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597), or the reversible FAAH inhibitor, 1-oxo-1-[5-(2-pyridyl)-2-yl]-7-phenylheptane (OL-135), decreased allodynia in both tests. This attenuation was completely blocked by pretreatment with either CB(1) or CB(2) receptor antagonists, but not by the TRPV1 receptor antagonist, capsazepine, or the opioid receptor antagonist, naltrexone. The novel MAGL inhibitor, 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) also attenuated mechanical and cold allodynia via a CB(1), but not a CB(2), receptor mechanism of action. Whereas URB597 did not elicit antiallodynic effects in FAAH(-/-) mice, the effects of JZL184 were FAAH-independent. Finally, URB597 increased brain and spinal cord AEA levels, whereas JZL184 increased 2-AG levels in these tissues, but no differences in either endo-cannabinoid were found between nerve-injured and control mice. These data indicate that inhibition of FAAH and MAGL reduces neuropathic pain through distinct receptor mechanisms of action and present viable targets for the development of analgesic therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“though ceiling effects and other methodological differences between studies may have precluded the detection of enhanced nociceptive behavior.”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Kinsey et al, 2009
In the citing paper
“However, other studies using knockout mice or selective inhibitors of CB 1 or CB 2 receptors show no alterations of nociceptive behavior in neuropathic pain models (Kinsey et al, 2009(Kinsey et al, , 2010) ) though ceiling effects and other methodological differences between studies may have precluded the detection of enhanced nociceptive behavior.”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Kinsey et al, 2009
In the citing paper
“Additionally both OL135 and URB597 are antinociceptive in FAAH+/+ mice, but fail to produce an effect in FAAH-/- mice.59”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [59]
In the citing paper
“OL135 and URB597 attenuate cold and mechanical allodynia in a manner that is dependent upon activation of both CB1 and CB2 receptors.59”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [59]
In the citing paper
“The novel MGL inhibitor, JZL184, attenuates CCI-induced mechanical and cold allodynia through indirect activation of the CB1 receptor; JZL184 was efficacious in attenuating neuropathic nociception in both FAAH+/+ and FAAH-/- mice.59”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative assessment of tactile allodynia in the rat paw
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(94)90144-9 · Cited by 7,740
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Spared nerve injury: an animal model of persistent peripheral neuropathic pain
Décosterd, I., & Woolf, C. J. (2000) · Pain · doi:10.1016/s0304-3959(00)00276-1 · Cited by 2,317
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Self-citationGaliègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D. J., Fur, G. L., & Casellas, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20780.x · Cited by 1,776
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Self-citationModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Samad, T. A., Moore, K. A., Sapirstein, A., Billet, S. E., Allchorne, A. J., Poole, S., Bonventre, J. V., & Woolf, C. J. (2001) · Nature · doi:10.1038/35068566 · Cited by 1,282
Flagged first, then by citations
2 of the 43 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 345
Wilkerson, J. L., Ghosh, S., Bağdaş, D., Mason, B. L., Crowe, M. S., Hsu, K., Wise, L. E., Kinsey, S. G., Damaj, M. I., Cravatt, B. F., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13469 · Cited by 57
Self-citationWoodhams, S. G., Wong, A., Barrett, D. A., Bennett, A. J., Chapman, V., & Alexander, S. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02179.x · Cited by 55
Ghosh, S., Kinsey, S. G., Liu, Q.-S., Hruba, L., McMahon, L. R., Grim, T. W., Merritt, C. R., Wise, L. E., Abdullah, R. A., Selley, D. E., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.222851 · Cited by 54
Self-citationSpradley, J. M., Guindon, J., & Hohmann, A. G. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.007 · Cited by 54
Mileni, M., Garfunkle, J., Ezzili, C., Kimball, F. S., Cravatt, B. F., Stevens, R. C., & Boger, D. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9012196 · Cited by 52
Self-citationA pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase
Carey, L. M., Slivicki, R. A., Leishman, E., Cornett, B., Mackie, K., Bradshaw, H. B., & Hohmann, A. G. (2016) · Molecular Pain · doi:10.1177/1744806916649192 · Cited by 53
Hossain, M. Z., Ando, H., Unno, S., & Kitagawa, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041423 · Cited by 54
Wilkerson, J. L., Gentry, K. R., Dengler, E. C., Wallace, J. A., Kerwin, A. A., Kuhn, M. N., Zvonok, A. M., Thakur, G. A., Makriyannis, A., & Milligan, E. D. (2012) · Brain and Behavior · doi:10.1002/brb3.44 · Cited by 51
Desroches, J., Charron, S., Bouchard, J., & Beaulieu, P. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.10.006 · Cited by 51
Małek, N., & Starowicz, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00257 · Cited by 51
Grim, T. W., Ghosh, S., Hsu, K.-L., Cravatt, B. F., Kinsey, S. G., & Lichtman, A. H. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.07.008 · Cited by 50
Self-citationJZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy
Khasabova, I. A., Yao, X., Paz, J., Lewandowski, C. T., Lindberg, A. E., Coicou, L., Burlakova, N., Simone, D. A., & Seybold, V. S. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.09.008 · Cited by 50
Cannabinoid receptors and pain
Starowicz, K., Małek, N., & Przewłocka, B. (2013) · Wiley Interdisciplinary Reviews Membrane Transport and Signalling · doi:10.1002/wmts.83 · Cited by 50
Feledziak, M., Lambert, D. M., Marchand‐Brynaert, J., & Muccioli, G. G. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842223 · Cited by 50
Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice
Donvito, G., Wilkerson, J. L., Damaj, M. I., & Lichtman, A. H. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.236182 · Cited by 50
Self-citationEzzili, C., Mileni, M., McGlinchey, N., Long, J. Z., Kinsey, S. G., Hochstatter, D. G., Stevens, R. C., Lichtman, A. H., Cravatt, B. F., Bilsky, E. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101597x · Cited by 49
Self-citationLevine, A. A., Liktor‐Busa, E., Lipinski, A. A., Couture, S. A., Balasubramanian, S., Aicher, S. A., Langlais, P. R., Vanderah, T. W., & Largent‐Milnes, T. M. (2021) · Biology of Sex Differences · doi:10.1186/s13293-021-00402-2 · Cited by 53
Lipases and their inhibitors in health and disease
Nomura, D. K., & Casida, J. E. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.04.004 · Cited by 50
The dynamic interaction between pain and opioid misuse
Wilson‐Poe, A. R., & Morón, J. A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13873 · Cited by 49
Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors
Gustin, D. J., Ma, Z., Min, X., Li, Y., Hedberg, C., Guimarães, C. R. W., Porter, A. C., Lindström, M., Lester-Zeiner, D., Xu, G., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.052 · Cited by 49
Sakın, Y. S., Dogrul, A. B., İlkaya, F., Seyrek, M., Ulaş, Ü. H., Gülşen, M., & Bagci, S. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12563 · Cited by 47
The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review
Fowler, C. J. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_4 · Cited by 46
Crowe, M. S., Leishman, E., Banks, M. L., Gujjar, R., Mahadevan, A., Bradshaw, H. B., & Kinsey, S. G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.13012 · Cited by 45
Self-citationSeillier, A., Aguilar, D. D., & Giuffrida, A. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.05.022 · Cited by 45
Reynoso-Moreno, I., Najar-Guerrero, I., Escareño, N., Flores-Soto, M. E., Gertsch, J., & Paredes, J. M. V. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b02979 · Cited by 48
An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present)
Bononi, G., Poli, G., Rizzolio, F., Tuccinardi, T., Macchia, M., Minutolo, F., & Granchi, C. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1841166 · Cited by 45
Schlosburg, J. E., Kinsey, S. G., Ignatowska-Jankowska, B., Ramesh, D., Abdullah, R. A., Tao, Q., Booker, L., Long, J. Z., Selley, D. E., Cravatt, B. F., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.212753 · Cited by 44
Self-citationMiller, L. L., Picker, M. J., Umberger, M. D., Schmidt, K. T., & Dykstra, L. A. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191478 · Cited by 44
Mechanism of platelet activation induced by endocannabinoids in blood and plasma
Brantl, S. A., Khandoga, A. L., & Siess, W. (2013) · Platelets · doi:10.3109/09537104.2013.803530 · Cited by 44
Cirino, T. J., Eans, S. O., Medina, J. M., Wilson, L., Mottinelli, M., Intagliata, S., McCurdy, C. R., & McLaughlin, J. P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00678 · Cited by 43
Wen, J., Jones, M., Tanaka, M., Selvaraj, P., Symes, A. J., Cox, B. M., & Zhang, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1045-9 · Cited by 43
Reddy, V. P., Grogan, D. P., Ahluwalia, M., Salles, É. L., Ahluwalia, P. K., Khodadadi, H., Alverson, K., Nguyen, A., Raju, S. P., Gaur, P., et al. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00203-4 · Cited by 45
Nasirinezhad, F., Jergová, S., Pearson, J. P., & Sagen, J. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.024 · Cited by 41
Mohammadi, S. A., & Christie, M. J. (2014) · Molecular Pain · doi:10.1186/1744-8069-10-64 · Cited by 40
Johnston, T. H., Huot, P., Fox, S. H., WAKEFIELD, J. D., Sykes, K. A., Bartolini, W. P., Milne, G. T., Pearson, J. P., & Brotchie, J. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169532 · Cited by 40
Starowicz, K., & Marzo, V. D. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.075 · Cited by 39
Afzal, O., Kumar, S., Kumar, R., Firoz, A., Jaggi, M., & Bawa, S. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.029 · Cited by 38
Nent, E., Nozaki, C., Schmöle, A., Otte, D. M., & Zimmer, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-43858-4 · Cited by 37
Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids.
Staniaszek, L., Norris, L., Kendall, D., Barrett, D., & Chapman, V (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00703.x · Cited by 36
Lichtman, A. H., Blankman, J. L., & Cravatt, B. F. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.069427 · Cited by 37
Self-citationMileni, M., Garfunkle, J., Ezzili, C., Cravatt, B. F., Stevens, R. C., & Boger, D. L. (2011) · Journal of the American Chemical Society · doi:10.1021/ja110877y · Cited by 35
Self-citationActivity-based proteomic and metabolomic approaches for understanding metabolism
Hunerdosse, D. M., & Nomura, D. K. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.02.001 · Cited by 35
Pietra, A. D., Giniatullin, R. A., & Savinainen, J. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031204 · Cited by 36
α-Ketoheterocycle-Based Inhibitors of Fatty Acid Amide Hydrolase (FAAH)
Otrubova, K., & Boger, D. L. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn2001206 · Cited by 35
Self-citationTherapeutical Potential of CB2 Receptors in Immune-Related Diseases
Leleu‐Chavain, N., Desreumaux, P., Chavatte, P., & Millet, R. (2014) · Current Molecular Pharmacology · doi:10.2174/1874467207666140219122337 · Cited by 37
Jiang, H., Ke, B., Liu, J., Ma, G., Hai, K., Gong, D., Yang, Z., & Zhou, C. (2018) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000003563 · Cited by 35
Cannabinoids modulate spontaneous synaptic activity in retinal ganglion cells
Middleton, T. P., & Protti, D. A. (2011) · Visual Neuroscience · doi:10.1017/s0952523811000198 · Cited by 34
Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats
Toniolo, E. F., Maique, E. T., Ferreira, W. A., Heimann, A. S., Ferro, E. S., Ramos‐Ortolaza, D. L., Miller, L. K., Devi, L. A., & Dale, C. S. (2014) · Peptides · doi:10.1016/j.peptides.2014.03.016 · Cited by 34
Cisneros, J. A., Björklund, E., González-Gil, I., Hu, Y., Canales, Á., Medrano, F. J., Romero, A., Ortega‐Gutiérrez, S., Fowler, C. J., & López-Rodríguez, M. L. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201327p · Cited by 33
Tanaka, M., Moran, S., Wen, J., Affram, K. O., Chen, T., Symes, A. J., & Zhang, Y. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0783-4 · Cited by 35
Otrubova, K., Brown, M. A., McCormick, M. S., Han, G. W., O’Neal, S. T., Cravatt, B. F., Stevens, R. C., Lichtman, A. H., & Boger, D. L. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4014997 · Cited by 32
Self-citationHicks, J. W., Parkes, J., Sadovski, O., Tong, J., Houle, S., Vasdev, N., & Wilson, A. A. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.04.008 · Cited by 35
Kornahrens, A. F., Cognetta, A. B., Brody, D. M., Matthews, M. L., Cravatt, B. F., & Boger, D. L. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02985 · Cited by 32
Self-citationSlivicki, R. A., Xu, Z., Mali, S. S., & Hohmann, A. G. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.002 · Cited by 31
Zhang, D., Sun, J., Yang, B. Y., Ma, S., Zhang, C., & Zhao, G. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2545806 · Cited by 31
Anandamide deficiency and heightened neuropathic pain in aged mice
Bishay, P., Häußler, A., Lim, H., Oertel, B. G., Galve‐Roperh, I., Ferreirós, N., & Tegeder, I. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.021 · Cited by 33
Wilkerson, J. L., Donvito, G., Grim, T. W., Abdullah, R. A., Ogasawara, D., Cravatt, B. F., & Lichtman, A. H. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.243808 · Cited by 30
Self-citationNavia‐Paldanius, D., Aaltonen, N., Lehtonen, M., Savinainen, J. R., Taschler, U., Radner, F. P. W., Zimmermann, R., & Laitinen, J. T. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.06.005 · Cited by 30
Vaitheesvaran, B., Yang, L., Hartil, K., Glaser, S. T., Yazulla, S., Bruce, J. E., & Kurland, I. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033717 · Cited by 29
Chicca, A., Arena, C., & Manera, C. (2016) · Recent Patents on CNS Drug Discovery · doi:10.2174/1574889810999160603185126 · Cited by 29
Thomas, A., Okine, B. N., Finn, D. P., & Masocha, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110456 · Cited by 32
Otrubova, K., Cravatt, B. F., & Boger, D. L. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401820q · Cited by 29
Self-citationThe multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain
Małek, N., Kostrzewa, M., Makuch, W., Pajak, A., Kucharczyk, M. W., Piscitelli, F., Przewłocka, B., Marzo, V. D., & Starowicz, K. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.012 · Cited by 28
Donvito, G., Bağdaş, D., Toma, W. B., Rahimpour, E., Jackson, A. B., Meade, J. A., AlSharari, S. D., Kulkarni, A., Carroll, F. I., Lichtman, A. H., et al. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.06.014 · Cited by 28
Self-citationTargeting the endogenous cannabinoid system to treat neuropathic pain
Lau, B. K., & Vaughan, C. W. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00028 · Cited by 27
N-Acyl pyrazoles: Effective and tunable inhibitors of serine hydrolases
Otrubova, K., Chatterjee, S., Ghimire, S., Cravatt, B. F., & Boger, D. L. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.03.020 · Cited by 28
Self-citationIncreased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain
Khasabova, I. A., Holman, M. A., Morse, T., Burlakova, N., Coicou, L. G., Harding-Rose, C., Simone, D. A., & Seybold, V. S. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.018 · Cited by 26
Wilkerson, J. L., Curry, Z. A., Kinlow, P. D., Mason, B. L., Hsu, K., van der Stelt, M., Cravatt, B. F., & Lichtman, A. H. (2018) · Pain · doi:10.1097/j.pain.0000000000001199 · Cited by 27
Self-citationAhmed, M. M., Rajpal, S., Sweeney, C., Gerovac, T. A., Allcock, B., McChesney, S. L., Patel, A. U., Tilghman, J. I., Miranpuri, G. S., & Resnick, D. K. (2010) · The Spine Journal · doi:10.1016/j.spinee.2010.08.015 · Cited by 26
Comparative studies of endocannabinoid modulation of pain
Paulsen, R. T., & Burrell, B. D. (2019) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2019.0279 · Cited by 26
Analgesic effects of FAAH inhibitor in the insular cortex of nerve-injured rats
Kim, M. J., Tanioka, M., Um, S. W., Hong, S., & Lee, B. H. (2018) · Molecular Pain · doi:10.1177/1744806918814345 · Cited by 25
Trexler, K. R., Eckard, M. L., & Kinsey, S. G. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.009 · Cited by 25
Self-citationHrubá, L., Seillier, A., Zaki, A., Cravatt, B. F., Lichtman, A. H., Giuffrida, A., & McMahon, L. R. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.222836 · Cited by 24
Self-citationWu, S., Yang, W.-H., Yeh, C.-C., & Huang, H.-C. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0805-7 · Cited by 24
Medina-Cleghorn, D., & Nomura, D. K. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.007 · Cited by 25
Björklund, E., Norén, E., Nilsson, J., & Fowler, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00974.x · Cited by 23
Kaczocha, M., Azim, S., Nicholson, J., Rebecchi, M. J., Lu, Y., Feng, T., Romeiser, J. L., Reinsel, R. A., Rizwan, S., Shodhan, S., et al. (2018) · BMC Anesthesiology · doi:10.1186/s12871-018-0489-5 · Cited by 23
Potential of Endocannabinoids to Control Bladder Pain
Bjorling, D. E., & Wang, Z.-Y. (2018) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2018.00017 · Cited by 24
Guadalupi, L., Mandolesi, G., Vanni, V., Balletta, S., Caioli, S., Pavlovic, A., De Vito, F., Fresegna, D., Sanna, K., Vitiello, L., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109940 · Cited by 22
Tosun, N. C., Gündüz, Ö., & Ulugöl, A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1251-x · Cited by 22
Combination Drug Therapy for Pain following Chronic Spinal Cord Injury
Hama, A. T., & Sagen, J. (2012) · Pain Research and Treatment · doi:10.1155/2012/840486 · Cited by 22
Analgesic Drugs Combinations in the Treatment of Different Types of Pain
Ortiz, M. I., Molina, M. A. R., Arai, Y.-C. P., & Romanò, C. L. (2012) · Pain Research and Treatment · doi:10.1155/2012/612519 · Cited by 22
Sim‐Selley, L. J., Wilkerson, J. L., Burston, J. J., Hauser, K. F., McLane, V. D., Welch, S. P., Lichtman, A. H., & Selley, D. E. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.248260 · Cited by 21
Self-citationNawata, Y., Yamaguchi, T., Fukumori, R., & Yamamoto, T. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy086 · Cited by 21
Nass, S. R., Steele, F. F., Ware, T. B., Libby, A. H., Hsu, K., & Kinsey, S. G. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0177 · Cited by 20
Self-citationLimebeer, C. L., Abdullah, R. A., Rock, E. M., Imhof, E., Wang, K., Lichtman, A. H., & Parker, L. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3282-7 · Cited by 21
Self-citationCrowe, M. S., Wilson, C. D., Leishman, E., Prather, P. L., Bradshaw, H. B., Banks, M. L., & Kinsey, S. G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14055 · Cited by 20
Self-citationWang, Y., & Burrell, B. D. (2017) · Journal of Neurophysiology · doi:10.1152/jn.00092.2017 · Cited by 20
Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson, J. L., Bilbrey, J. A., Felix, J. S., Makriyannis, A., & McMahon, L. R. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173192 · Cited by 20
Wilkerson, J. L., & Milligan, E. D. (2011) · ISRN Anesthesiology · doi:10.5402/2011/593894 · Cited by 20
Morgan, A., Adank, D. N., Johnson, K., Butler, E. C., & Patel, S. (2022) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14949 · Cited by 20
Alterations in the Anandamide Metabolism in the Development of Neuropathic Pain
Małek, N., Kucharczyk, M. W., & Starowicz, K. (2014) · BioMed Research International · doi:10.1155/2014/686908 · Cited by 19
The endocannabinoid system: Novel targets for treating cancer induced bone pain
Sun, J., Zhou, Y., Chen, S., Wang, X., Xu, B., Li, D., Tian, Y., & Ye, D. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109504 · Cited by 19
Wu, M. M., Zhang, X., Asher, M. J., & Thayer, S. A. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146467 · Cited by 19
Pietra, A. D., Savinainen, J. R., & Giniatullin, R. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084407 · Cited by 19
The endocannabinoid system as a therapeutic target in neuropathic pain: a review
Quintero, J.-M., Díaz, L. E., Galve‐Roperh, I., Bustos, R., Leon, M.-X., Beltran, S., & Dodd, S. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2407824 · Cited by 18
Horváth, E., Woodhams, S. G., Nyilas, R., Henstridge, C. M., Kano, M., Sakimura, K., Watanabe, M., & Katona, I. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12470 · Cited by 18
MAGL inhibition modulates gastric secretion and motility following NSAID exposure in mice
Crowe, M. S., & Kinsey, S. G. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.006 · Cited by 18
Self-citationConformational gating, dynamics and allostery in human monoacylglycerol lipase
Tyukhtenko, S. I., Ma, X., Rajarshi, G., Karageorgos, I. L., Anderson, K. W., Hudgens, J. W., Guo, J. J., Nasr, M. L., Zvonok, N., Vemuri, K. V., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75497-5 · Cited by 20
Afzal, O., Altamimi, A. S. A., Shahroz, M. M., Sharma, H. K., Riadi, Y., & Hassan, M. Q. (2021) · Molecules · doi:10.3390/molecules26082389 · Cited by 18
Metadata
- Authors
- Kinsey, S. G., Long, J. Z., O’Neal, S. T., Abdullah, R. A., Poklis, J. L., Boger, D. L., Cravatt, B. F., & Lichtman, A. H.
- Affiliations
- Virginia Commonwealth University (US)
- Scripps Research Institute (US)
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 330
- Issue
- 3
- Pages
- 902-910
- ISSN
- 0022-3565 (ISSN-L)
- PMC
- PMC2729802
- OpenAlex
- W2132380973
- Cited by
- 330
- References
- 43
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 13 · 2023: 8 · 2022: 7 · 2021: 15 · 2020: 9 · 2019: 14 · 2018: 21 · 2017: 24 · 2016: 16 · 2015: 21 · 2014: 35 · 2013: 29 · 2012: 33
- FWCI
- 24.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institute of International Education
- National Institute on Drug Abuse (DA015197, P01DA009789, DA-017259, R01DA015197, DA009789-11, DA007027-32, P01DA017259, DA 009789, DA015648, T32DA007027, DA007027)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- neuropathic pain, endocannabinoid system, fatty acid amide hydrolase, monoacylglycerol lipase, anandamide, 2-arachidonoylglycerol, CB1 receptor, CB2 receptor, URB597, JZL184, chronic constriction injury, mechanical allodynia, cold allodynia, analgesic drug development
- MeSH terms
- Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Arachidonic Acids, Benzamides, Carbamates, Cold Temperature, Enzyme Inhibitors, Glycerides, Hyperalgesia, Male, Mice, Inbred C57BL, Monoacylglycerol Lipases, Narcotic Antagonists, Pain, Pain Measurement, Peripheral Nervous System Diseases, Piperidines, Pyridines, Analgesics, Non-Narcotic, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, TRPV Cation Channels, Mice, Benzodioxoles, Polyunsaturated Alkamides, Cannabinoid Receptor Modulators, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review